EAM
ALDR

Eagle Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Eagle Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,427,922
Closed -$16.5M – 651
2017
Q4 		$16.5M Sell
1,427,922
-3,145
-0.2% -$35.1K 0.09% 257
2017
Q3 		$17.6M Sell
1,431,067
-325,440
-19% -$3.39M 0.1% 270
2017
Q2 		$20.1M Buy
1,756,507
+601,242
+52% +$11.1M 0.12% 237
2017
Q1 		$24M Buy
1,155,265
+35,726
+3% +$791K 0.15% 199
2016
Q4 		$23.3M Buy
1,119,539
+5,001
+0.4% +$130K 0.15% 196
2016
Q3 		$36.5M Sell
1,114,538
-5,078
-0.5% -$155K 0.25% 124
2016
Q2 		$28M Sell
1,119,616
-23,477
-2% -$635K 0.19% 158
2016
Q1 		$28M Sell
1,143,093
-53,412
-4% -$1.24M 0.19% 165
2015
Q4 		$39.5M Buy
1,196,505
+36,274
+3% +$1.23M 0.26% 133
2015
Q3 		$38M Sell
1,160,231
-226,739
-16% -$9.64M 0.26% 131
2015
Q2 		$73.5M Buy
1,386,970
+259,737
+23% +$9.45M 0.41% 80
2015
Q1 		$32.5M Buy
+1,127,233
New +$30.9M 0.19% 169

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Eagle Asset Management's ALDR Position: Q1 2018 in Review

Eagle Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 1,427,922 shares — an estimated $16.5M sold.

Eagle Asset Management first reported a position in ALDR in Q1 2015 and held it in 12 quarters. The position peaked at $73.5M in Q2 2015. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Eagle Asset Management reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Eagle Asset Management sold 1,427,922 Alder Biopharmaceuticals shares in Q1 2018, an estimated $16.5M.
  • Eagle Asset Management first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 12 quarters.
  • Eagle Asset Management's Alder Biopharmaceuticals position peaked at $73.5M in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Eagle Asset Management's 13F filing for Q1 2018, filed 9 May 2018.